Reduction of Plasma Cholesterol Levels and Induction of Hepatic LDL Receptor by Cerivastatin Sodium (CAS 143201-11-0, BAY w 6228), a New Inhibitor of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase, in Dogs

By Yasunobu Yuji   Hayashi Kozo   Shingu Tetsuji   Nomura Katsuhiko   Ohkura Yoshifumi   Tanaka Kouichi   Kuga Yoshio   Nomura Syu-ichi   Ohtani Harumi   Nishimura Takaharu   Matsuura Hideo   Kajiyama Goro  

Cardiovascular Drugs and Therapy, Vol. 11, Iss. 4, 1997-09 ,pp. : 567-574

Springer Publishing Company

Access to resources Recommend Favorite

Cerivastatin: the low-dose HMG-COA reductase inhibitor

By Tikkanen M.J.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 1, 2000-01 ,pp. : 161-166

Informa Healthcare

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitor (Statin) Therapy and Coronary Atherosclerosis in Japanese Subjects: Role of High-Density Lipoprotein Cholesterol

By Tani Shigemasa   Nagao Ken   Hirayama Atsushi  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 6, 2011-12 ,pp. : 411-417

Adis International

Access to resources Recommend Favorite

HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent ''direct'' effects on atherosclerotic vessels in high cholesterol diet-fed rabbits

By Mitani H.   Egashira K.   Kimura M.  

Pharmacological Research, Vol. 48, Iss. 5, 2003-11 ,pp. : 417-427

Elsevier

Access to resources Recommend Favorite

Synthesis, Crystal Structure and Biological Evaluation of 4, 5, 6, 7-tetrahydropravastatin as HMG-CoA Reductase Inhibitor

By  

Letters in Drug Design & Discovery, Vol. 8, Iss. 9, 2011-11 ,pp. : 884-888

Bentham Science Publishers

Access to resources Recommend Favorite